35 completed, 7 recruiting, 4 not yet recruiting, 4 unknown. 41 Phase 1, 7 Not applicable, 6 Phase 2, 3 Phase 3.
Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-04-01 | 2026-07-30 |
| A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug), Placebo - Safety, Tolerability | Phase 1 | Not yet recruiting | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 64 | 2027-01-01 | 2026-10-16 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly), Placebo (microcrystalline cellulose) - Safety, Tolerability | Not applicable | Completed | Kioga Inc. | 8 | 2025-07-07 | 2026-06-22 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) GenSci134, Placebo, Recombinant Human Growth Hormone Injection (Norditropin®) - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 64 | 2025-06-09 | 2026-04-14 |
| Single Ascending Dose and Multiple Ascending Dose Study of AVR-48 AVR-48, Placebo - Safety Issues, Tolerability | Phase 1 | Not yet recruiting | AyuVis Research, Inc. | 48 | 2025-06-01 | 2025-04-06 |
| A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults Nezavist SDD, Placebo - Healthy, Safety Evaluation of Escalating Doses | Phase 1 | Terminated | Lohocla Research Corporation | 29 | 2025-02-28 | 2026-09-08 |
| Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers. Placebo (SAD), RCS-21 (SAD), Placebo (MD) - Healthy Volunteers, Safety | Phase 1 | Recruiting | RNATICS GmbH | 32 | 2025-02-18 | 2026-10-26 |
| A Phase 1 Study of Y-3 in US Healthy Volunteers. Y-3 for injection, Placebo - Safety, Tolerability | Phase 1 | Completed | Neurodawn Pharmaceutical Co., Ltd. | 20 | 2025-02-04 | 2025-12-18 |
| Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12 Oral probiotic Streptococcus salivarius eK12, Placebo - Safety, Tolerability | Not applicable | Completed | Liaquat University of Medical & Health Sciences | 29 | 2024-11-01 | 2025-09-05 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease GenSci098, GenSci098 Placebo - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 76 | 2024-09-24 | 2026-02-11 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| SB17170 Phase1 Trial in Healthy Volunteer SB17170, Placebo - Safety Issues, Tolerability | Phase 1 | Completed | SPARK Biopharma | 64 | 2023-05-24 | 2024-03-21 |
| Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets) - Safety, Tolerability | Phase 1 | Completed | RH Nanopharmaceuticals | 64 | 2023-03-09 | 2023-05-06 |
| Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo - Pharmacokinetics, Safety | Phase 1 | Completed | Usona Institute | 54 | 2022-12-27 | 2023-11-30 |
| Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study Combinations of Oral Blood Glucose Lowering Drugs - Efficacy, Safety | Completed | Getz Pharma | 190 | 2022-12-01 | 2025-03-20 |
Showing 20 of 54. Sign in to see all of them.
Anxiety Disorders (2) · Marijuana Abuse (2) · Neoplasms (2) · Respiratory Aspiration (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Carcinoma, Ovarian Epithelial (1) · Drug Resistant Epilepsy (1) · Dwarfism, Pituitary (1) · Dyskinesias (1) · Graves Disease (1) · Graves Ophthalmopathy (1) · Lymphoma, Follicular (1) · Otitis (1) · Pain (1)
Central Nervous System Diseases (6) · Nervous System Diseases (6) · Brain Diseases (5) · Mental Disorders (5) · Endocrine System Diseases (4) · Immune System Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Autoimmune Diseases (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Chemically-Induced Disorders (2) · Exophthalmos (2) · Eye Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Injections (2) · Moxifloxacin (2) · microcrystalline cellulose (2) · ACT-462206 (1) · AZD-3043 (1) · AZD3839 (1) · AZD9819 (1) · AZD9977 (1) · Clarithromycin (1) · Didanosine (1) · Diet, Ketogenic (1) · Dronabinol (1) · Drug Interactions (1) · Enclomiphene (1) · Growth Hormone (1)
AstraZeneca (8) · Changchun GeneScience Pharmaceutical Co., Ltd. (4) · Sichuan Huiyu Pharmaceutical Co., Ltd (3) · CannaXan GmbH (2) · Chattem, Inc. (2) · Hangzhou Yirui Pharmaceutical Technology Co., Ltd (2) · Actelion (1) · AnaMar AB (1) · Anhui Provincial Hospital (1) · Astellas Pharma Europe B.V. (1) · Ativus Farmaceutica Ltda (1) · AyuVis Research, Inc. (1) · BioGaia AB (1) · Campus Bio-Medico University (1) · Cinclus Pharma Holding AB (1)
United States (16) · China (8) · United Kingdom (7) · Germany (6) · Pakistan (3) · Brazil (2) · Sweden (2) · Indonesia (1) · Mexico (1) · Netherlands (1) · South Korea (1) · Vietnam (1)
Brendan Smyth (2) · Daniel J Hogan, MD (2) · Elie Fiss (2) · Billings W Billings, MD (1) · Colleen Jensen (1) · Darren Wilbraham (1) · David Mathews, MD (1) · Dr Darren Wilbraham, MBBS DCPSA (1) · Dr Paul Bjornsson (1) · Erik Rein-Hedin, MD (1) · Huifang Zhou, PHD (1) · Izhar Hasan, MD, PhD (1)
PMID 12750546, PMID 23103177, PMID 25703312, PMID 31601801, PMID 32087818, PMID 33148815, PMID 34487721, PMID 37185136, PMID 37832977, PMID 38258274, PMID 39858024, PMID 41438195
2015 (2), R44AA024905 (1)